OTCMKTS:RGRX - Regenerx Biopharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.2099 +0.01 (+5.00 %)
(As of 05/21/2018 01:17 AM ET)
Previous Close$0.2099
Today's Range$0.2099 - $0.2099
52-Week Range$0.1390 - $0.38
Volume18,100 shs
Average Volume58,934 shs
Market Capitalization$25.11 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.79

About Regenerx Biopharmaceuticals (OTCMKTS:RGRX)

Regenerx Biopharmaceuticals logoRegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It also evaluates the commercial development of peptide fragments and derivatives of Tß4 for potential cosmeceutical and other personal care uses. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was founded in 1982 and is headquartered in Rockville, Maryland.

Receive RGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for RGRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:RGRX
CUSIPN/A
Phone301-208-9191

Debt

Debt-to-Equity RatioN/A
Current Ratio1.22
Quick Ratio0.10

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$50,000.00
Price / Sales502.25
Cash Flow$0.0026 per share
Price / Cash81.42
Book Value($0.02) per share
Price / Book-10.50

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$280,000.00
Net Margins-1,591.23%
Return on Equity-3.35%
Return on Assets-215.95%

Miscellaneous

Employees10
Outstanding Shares119,640,000

Regenerx Biopharmaceuticals (OTCMKTS:RGRX) Frequently Asked Questions

What is Regenerx Biopharmaceuticals' stock symbol?

Regenerx Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "RGRX."

When is Regenerx Biopharmaceuticals' next earnings date?

Regenerx Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 21st 2018. View Earnings Estimates for Regenerx Biopharmaceuticals.

What price target have analysts set for RGRX?

1 brokerages have issued 12 month target prices for Regenerx Biopharmaceuticals' shares. Their predictions range from $1.50 to $1.50. On average, they expect Regenerx Biopharmaceuticals' share price to reach $1.50 in the next year. View Analyst Ratings for Regenerx Biopharmaceuticals.

Who are some of Regenerx Biopharmaceuticals' key competitors?

Who are Regenerx Biopharmaceuticals' key executives?

Regenerx Biopharmaceuticals' management team includes the folowing people:
  • Dr. Allan L. Goldstein Ph.D., Founder, Chairman, Chief Scientific Officer and Chairman of Scientific Advisory Board (Age 80)
  • Mr. J. J. Finkelstein, Chief Exec. Officer, Pres and Director (Age 66)
  • Mr. Dane R. Saglio, Chief Financial Officer (Age 60)
  • Mr. Alan Klein MBA, Chief Bus. Officer
  • Dr. Nabila A. Turjman Ph.D., Exec. Director of Regulatory Affairs

Has Regenerx Biopharmaceuticals been receiving favorable news coverage?

News coverage about RGRX stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Regenerx Biopharmaceuticals earned a media sentiment score of 0.10 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 46.39 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Regenerx Biopharmaceuticals?

Shares of RGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Regenerx Biopharmaceuticals' stock price today?

One share of RGRX stock can currently be purchased for approximately $0.2099.

How big of a company is Regenerx Biopharmaceuticals?

Regenerx Biopharmaceuticals has a market capitalization of $25.11 million and generates $50,000.00 in revenue each year. Regenerx Biopharmaceuticals employs 10 workers across the globe.

How can I contact Regenerx Biopharmaceuticals?

Regenerx Biopharmaceuticals' mailing address is 15245 SHADY GROVE ROAD SUITE 470, ROCKVILLE MD, 20850. The biopharmaceutical company can be reached via phone at 301-208-9191 or via email at [email protected]


MarketBeat Community Rating for Regenerx Biopharmaceuticals (RGRX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  58 (Vote Outperform)
Underperform Votes:  45 (Vote Underperform)
Total Votes:  103
MarketBeat's community ratings are surveys of what our community members think about Regenerx Biopharmaceuticals and other stocks. Vote "Outperform" if you believe RGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Regenerx Biopharmaceuticals (OTCMKTS:RGRX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Regenerx Biopharmaceuticals in the last 12 months. Their average twelve-month price target is $1.50, suggesting that the stock has a possible upside of 614.63%. The high price target for RGRX is $1.50 and the low price target for RGRX is $1.50. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $1.50$1.50$1.50$1.50
Price Target Upside: 614.63% upside455.56% upside455.56% upside455.56% upside

Regenerx Biopharmaceuticals (OTCMKTS:RGRX) Consensus Price Target History

Price Target History for Regenerx Biopharmaceuticals (OTCMKTS:RGRX)

Regenerx Biopharmaceuticals (OTCMKTS:RGRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
11/1/2017HC WainwrightLower Price TargetBuy$2.00 ➝ $1.50View Rating Details
(Data available from 5/21/2016 forward)

Earnings

Regenerx Biopharmaceuticals (OTCMKTS:RGRX) Earnings History and Estimates Chart

Earnings by Quarter for Regenerx Biopharmaceuticals (OTCMKTS:RGRX)

Regenerx Biopharmaceuticals (OTCMKTS RGRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/21/2018        
11/14/2017Q3 2017($0.01)$0.01 million$0.01 millionViewN/AView Earnings Details
11/14/2016Q3 2016$0.01$0.01 million$0.01 millionViewN/AView Earnings Details
5/16/2016Q1 2016($0.03)$0.25 million$0.06 millionViewN/AView Earnings Details
11/13/2015Q3 2015($0.01)$0.01 millionViewN/AView Earnings Details
8/14/2015Q2 2015($0.02)$0.01 millionViewN/AView Earnings Details
5/15/2015Q1 2015($0.02)$0.04 millionViewN/AView Earnings Details
11/14/2011Q3 2011($0.02)($0.03)ViewN/AView Earnings Details
8/5/2011Q2 2011($0.02)ViewN/AView Earnings Details
5/16/2011Q1 2011($0.02)($0.02)ViewN/AView Earnings Details
11/13/2008Q3 2008($0.05)ViewN/AView Earnings Details
8/11/2008Q2 2008($0.06)ViewN/AView Earnings Details
3/28/2008Q4 2007($0.08)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Regenerx Biopharmaceuticals (OTCMKTS:RGRX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Regenerx Biopharmaceuticals (OTCMKTS RGRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.10%
Institutional Ownership Percentage: 0.15%
Insider Trading History for Regenerx Biopharmaceuticals (OTCMKTS:RGRX)

Regenerx Biopharmaceuticals (OTCMKTS RGRX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/13/2018Spa EssetifinMajor ShareholderBuy17,933,673$0.23$4,124,744.79View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Regenerx Biopharmaceuticals (OTCMKTS RGRX) News Headlines

Source:
DateHeadline
ReGenTree Presents Results of a Comparison Study of RGN-259 and Approved Prescription Drugs for Dry Eye Syndrome in a Mouse Model at ARVOReGenTree Presents Results of a Comparison Study of RGN-259 and Approved Prescription Drugs for Dry Eye Syndrome in a Mouse Model at ARVO
finance.yahoo.com - May 2 at 5:35 PM
GtreeBNT Discloses Preliminary Observations from Seventeen NK Patients Treated with RGN-259 Eye DropsGtreeBNT Discloses Preliminary Observations from Seventeen NK Patients Treated with RGN-259 Eye Drops
finance.yahoo.com - April 25 at 5:28 PM
Regenerx Biopharmaceuticals (RGRX) Given a $2.00 Price Target by HC Wainwright AnalystsRegenerx Biopharmaceuticals (RGRX) Given a $2.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 9 at 8:06 PM
RegeneRx Announces Outcome of FDA Discussions for Development of RGN-259 for Dry Eye SyndromeRegeneRx Announces Outcome of FDA Discussions for Development of RGN-259 for Dry Eye Syndrome
finance.yahoo.com - April 9 at 8:19 AM
Regenerx Biopharmaceuticals (RGRX) Price Target Cut to $1.50Regenerx Biopharmaceuticals (RGRX) Price Target Cut to $1.50
www.americanbankingnews.com - April 2 at 2:04 PM
Spa Essetifin Acquires 17,933,673 Shares of RegeneRx Biopharmaceuticals Inc (RGRX) StockSpa Essetifin Acquires 17,933,673 Shares of RegeneRx Biopharmaceuticals Inc (RGRX) Stock
www.americanbankingnews.com - March 14 at 7:10 PM
RegeneRx Receives Notice of Allowance of U.S. Patent for Treatment of Corneal WoundsRegeneRx Receives Notice of Allowance of U.S. Patent for Treatment of Corneal Wounds
finance.yahoo.com - March 14 at 7:06 PM
RegeneRx Receives "Decision to Grant" European Patent For Treatment of Peripheral NeuropathyRegeneRx Receives "Decision to Grant" European Patent For Treatment of Peripheral Neuropathy
finance.yahoo.com - March 12 at 9:16 AM
RegeneRx Secures $1 Million in FundingRegeneRx Secures $1 Million in Funding
finance.yahoo.com - March 2 at 6:09 PM
Key U.S. Dry Eye Patent Issued to RegeneRxKey U.S. Dry Eye Patent Issued to RegeneRx
finance.yahoo.com - February 22 at 8:22 AM
RegeneRx Receives Canadian Patent for Treating Neurological Injury and DamageRegeneRx Receives Canadian Patent for Treating Neurological Injury and Damage
finance.yahoo.com - February 14 at 9:52 AM
RegeneRx Biopharmaceuticals (RGRX) and Alexza Pharmaceuticals (ALXA) Head to Head ContrastRegeneRx Biopharmaceuticals (RGRX) and Alexza Pharmaceuticals (ALXA) Head to Head Contrast
www.americanbankingnews.com - December 18 at 11:36 PM
Critical Review: RegeneRx Biopharmaceuticals (RGRX) & Alexza Pharmaceuticals (ALXA)Critical Review: RegeneRx Biopharmaceuticals (RGRX) & Alexza Pharmaceuticals (ALXA)
www.americanbankingnews.com - December 18 at 9:22 PM
Head-To-Head Comparison: RegeneRx Biopharmaceuticals (RGRX) and Endo International (ENDP)Head-To-Head Comparison: RegeneRx Biopharmaceuticals (RGRX) and Endo International (ENDP)
www.americanbankingnews.com - December 15 at 9:14 AM
Head to Head Analysis: Biodel (ALBO) and RegeneRx Biopharmaceuticals (RGRX)Head to Head Analysis: Biodel (ALBO) and RegeneRx Biopharmaceuticals (RGRX)
www.americanbankingnews.com - December 14 at 7:16 AM
Endo International (ENDP) vs. RegeneRx Biopharmaceuticals (RGRX) Head-To-Head ContrastEndo International (ENDP) vs. RegeneRx Biopharmaceuticals (RGRX) Head-To-Head Contrast
www.americanbankingnews.com - December 13 at 1:34 PM
Head-To-Head Review: RegeneRx Biopharmaceuticals (RGRX) & Endo International (ENDP)Head-To-Head Review: RegeneRx Biopharmaceuticals (RGRX) & Endo International (ENDP)
www.americanbankingnews.com - December 13 at 7:52 AM
RegeneRx Biopharmaceuticals (RGRX) vs. Alexza Pharmaceuticals (ALXA) Critical AnalysisRegeneRx Biopharmaceuticals (RGRX) vs. Alexza Pharmaceuticals (ALXA) Critical Analysis
www.americanbankingnews.com - December 10 at 5:22 AM
RegeneRx Releases Annual Letter to ShareholdersRegeneRx Releases Annual Letter to Shareholders
finance.yahoo.com - December 7 at 4:03 PM
Contrasting Alexza Pharmaceuticals (ALXA) and RegeneRx Biopharmaceuticals (RGRX)Contrasting Alexza Pharmaceuticals (ALXA) and RegeneRx Biopharmaceuticals (RGRX)
www.americanbankingnews.com - November 30 at 9:58 PM
RegeneRx Biopharmaceuticals (RGRX) versus Endo International (ENDP) Critical ContrastRegeneRx Biopharmaceuticals (RGRX) versus Endo International (ENDP) Critical Contrast
www.americanbankingnews.com - November 29 at 9:44 PM
RegeneRx Biopharmaceuticals, Inc. :RGRX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017RegeneRx Biopharmaceuticals, Inc. :RGRX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 8:49 AM
Biodel (ALBO) and RegeneRx Biopharmaceuticals (RGRX) Head to Head SurveyBiodel (ALBO) and RegeneRx Biopharmaceuticals (RGRX) Head to Head Survey
www.americanbankingnews.com - November 23 at 9:32 AM
Financial Comparison: RegeneRx Biopharmaceuticals (RGRX) and Biodel (ALBO)Financial Comparison: RegeneRx Biopharmaceuticals (RGRX) and Biodel (ALBO)
www.americanbankingnews.com - November 23 at 3:12 AM
Financial Contrast: Alexza Pharmaceuticals (ALXA) versus RegeneRx Biopharmaceuticals (RGRX)Financial Contrast: Alexza Pharmaceuticals (ALXA) versus RegeneRx Biopharmaceuticals (RGRX)
www.americanbankingnews.com - November 19 at 11:44 AM
Tβ4s Role in Treatment of Eye Diseases Showcased at 5th International Thymosin SymposiumTβ4's Role in Treatment of Eye Diseases Showcased at 5th International Thymosin Symposium
finance.yahoo.com - November 18 at 11:20 AM
Reviewing Endo International PLC (ENDP) and RegeneRx Biopharmaceuticals (RGRX)Reviewing Endo International PLC (ENDP) and RegeneRx Biopharmaceuticals (RGRX)
www.americanbankingnews.com - November 16 at 5:42 AM
RegeneRx JV Announces Results of ARISE-2 Dry Eye TrialRegeneRx JV Announces Results of ARISE-2 Dry Eye Trial
finance.yahoo.com - October 31 at 8:36 AM
RegeneRx Completes License Expansion for RGN-137 in Europe, S. Korea, Japan, Canada and AustraliaRegeneRx Completes License Expansion for RGN-137 in Europe, S. Korea, Japan, Canada and Australia
finance.yahoo.com - August 31 at 9:24 AM
RegeneRx Collaborators Receive Notice of Intent to Grant EU Patent for the Treatment of Peripheral NeuropathyRegeneRx Collaborators Receive Notice of 'Intent to Grant' EU Patent for the Treatment of Peripheral Neuropathy
finance.yahoo.com - August 15 at 6:43 AM
RegeneRx Updates on RGN-259 Phase 3 Dry Eye TrialRegeneRx Updates on RGN-259 Phase 3 Dry Eye Trial
finance.yahoo.com - July 28 at 7:16 AM
Report: Sheriff Clarke Plagiarized Parts Of Thesis On Homeland SecurityReport: Sheriff Clarke Plagiarized Parts Of Thesis On Homeland Security
www.huffingtonpost.com - May 21 at 12:03 AM
Heres Why Democrats Are Not Storming The Gates, Demanding ImpeachmentHere's Why Democrats Are Not Storming The Gates, Demanding Impeachment
www.huffingtonpost.com - May 18 at 10:38 AM
OPEC Loses Power of Surprise as Majority Back Cuts ExtensionOPEC Loses Power of Surprise as Majority Back Cuts Extension
www.bloomberg.com - May 18 at 10:38 AM
Jury Acquits Tulsa Officer Betty Shelby in Shooting Death of Terence CrutcherJury Acquits Tulsa Officer Betty Shelby in Shooting Death of Terence Crutcher
www.nbcnews.com - May 18 at 10:38 AM
House Dems Smash Fundraising Records Ahead of MidtermsHouse Dems Smash Fundraising Records Ahead of Midterms
www.nbcnews.com - May 18 at 10:38 AM
Trump responds to special counsel, calls Russia probe single greatest witch huntTrump responds to special counsel, calls Russia probe 'single greatest witch hunt'
abcnews.go.com - May 18 at 10:38 AM
El-Sisi Pledges More Aid as Egypts Poor Struggle With InflationEl-Sisi Pledges More Aid as Egypt's Poor Struggle With Inflation
www.bloomberg.com - May 17 at 5:31 AM
Apple Supplier AAC Falls as Short Seller Gotham Questions ProfitApple Supplier AAC Falls as Short Seller Gotham Questions Profit
www.bloomberg.com - May 11 at 12:44 AM
Minnesota Health Officials Seek $5 Million for Measles OutbreakMinnesota Health Officials Seek $5 Million for Measles Outbreak
www.nbcnews.com - May 10 at 7:44 PM
Michael Kors Faces Tougher Market After Coach-Kate Spade MergerMichael Kors Faces Tougher Market After Coach-Kate Spade Merger
www.bloomberg.com - May 10 at 11:14 AM
Illegal border crossings continue to drop, even as Trump ramps up anti-immigration enforcementIllegal border crossings continue to drop, even as Trump ramps up anti-immigration enforcement
www.usatoday.com - May 9 at 7:04 PM
Officials on alert after tunnel collapse at Washington nuclear waste siteOfficials on alert after tunnel collapse at Washington nuclear waste site
www.latimes.com - May 9 at 7:04 PM
US warplanes among those barred from flying over Syrias safe zones in proposalUS warplanes among those barred from flying over Syria's 'safe zones' in proposal
www.foxnews.com - May 5 at 8:16 AM
US Air Force jets intercept Russian bombers, fighter jets near AlaskaUS Air Force jets intercept Russian bombers, fighter jets near Alaska
www.foxnews.com - May 4 at 8:47 AM
Warren: After Trump, ‘I Wonder If America Will Ever Be Ready for a Male President Again’Warren: After Trump, ‘I Wonder If America Will Ever Be Ready for a Male President Again’
www.nbcnews.com - May 4 at 12:27 AM
Susan Rice wont testify before Senate on Russia hacking, unmaskingSusan Rice won't testify before Senate on Russia hacking, 'unmasking'
www.foxnews.com - May 4 at 12:27 AM
Alton Sterling Shooting: Justice Department Announces No Federal ChargesAlton Sterling Shooting: Justice Department Announces No Federal Charges
www.nbcnews.com - May 3 at 7:26 PM
Tearful Jimmy Kimmel Breaks Down Revealing Newborn Sons Heart SurgeryTearful Jimmy Kimmel Breaks Down Revealing Newborn Son's Heart Surgery
www.huffingtonpost.com - May 2 at 5:21 PM
Merkel sees EU, Gulf states making progress on free trade deal Merkel sees EU, Gulf states making progress on free trade deal
www.reuters.com - May 1 at 10:20 AM

SEC Filings

Regenerx Biopharmaceuticals (OTCMKTS:RGRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Regenerx Biopharmaceuticals (OTCMKTS:RGRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Regenerx Biopharmaceuticals (OTCMKTS RGRX) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.